Furthermore, apigenin treatment reduces the level of α-synuclein while positively regulating the protein expression of tyrosine hydrolase (TH) and dopamine D2 receptor, indicating that apigenin confers neuroprotectant properties that may serve as an alternative therapeutic for neurodegeneration disorders like PD [267,268]. Here, SNCA is linked to Parkinson disease.